Dr Shabber Zaveri, Chairman, HOD, Surgical Oncology, Manipal Hospital, Bengaluru and surgical oncologist Dr Mohammad Bashiruddin Inamdar admit that the patient’s will power, motivation and most importantly a disciplined lifestyle of exercise, diet and mental well-being saw him through
New Drug Combats Late-stage Prostate Cancer by Angela Mohan on July 12, 2021 at 11:18 AM
New treatment combats late stage prostate cancer by delivering beta radiation directly to tumour cells. It is well tolerated by patients and keeps them alive for longer compared to standard care, as per the phase 3 trial findings.
New approach, targets a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
International team of researchers set out to see whether Lu-PSMA-617 was more effective than standard care and recruited 831 patients with metastatic castration-resistant prostate cancer between June 2018 and October 2019. Patients were randomized to receive the treatment plus standard care or standard care alone.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan
January 26, 2021 GMT
SHANGHAI, Jan. 26, 2021 /PRNewswire/ Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. Hexvix® is a drug that preferentially accumulates in bladder cancer cells, making them glow bright pink during Blue Light Cystoscopy (BLC®). It is expected to meet a strong unmet need in the diagnosis and resection of non-muscle invasive bladder cancer (NMIBC) in Mainland China and Taiwan.